ABT vs EXEL: fair value comparison
Abbott Laboratories and Exelixis, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ABT currently sits closer to the top of our discount ranking. EXEL carries the stronger quality grade.
| ABT | EXEL | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $112.47 | $55.06 |
| 12-month range | $87.78–$131.46 | $37.18–$55.06 |
| Sector rank | #43 of 113 Healthcare | #48 of 113 Healthcare |
| Quality grade | B | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Overvalued | Fairly Valued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: ABT fair value analysis · EXEL fair value analysis